Integrated Analysis of circRNA-miRNA-mRNA ceRNA Network in Cardiac Hypertrophy

Yang-Hao Chen1, Ling-Feng Zhong1, Xia Hong2

  • 1The Key Laboratory of Cardiovascular Disease of Wenzhou, Department of Cardiology, The First Affiliated Hospital of WenZhou Medical University, WenZhou, China.

Frontiers in Genetics
|February 25, 2022
PubMed

Insights

This study identifies key circular RNAs (circRNAs) and their regulatory networks involved in cardiac hypertrophy, a heart condition. These findings offer new insights into the molecular mechanisms underlying this adaptive cardiac response.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genomics

Background:

  • Cardiac hypertrophy is an adaptive response to increased hemodynamic load.
  • Abnormal non-coding RNA expression is increasingly linked to myocardial hypertrophy.
  • Circular RNAs (circRNAs) are implicated in cardiac hypertrophy, but their regulatory networks are poorly understood.

Purpose of the Study:

  • To systematically analyze circRNA-related competing endogenous RNA (ceRNA) regulatory networks in cardiac hypertrophy.
  • To identify key circRNAs, messenger RNAs (mRNAs), and microRNAs (miRNAs) involved in this process.

Main Methods:

  • Utilized public databases for prediction and screening of differentially expressed mRNAs and miRNAs.
  • Constructed a circRNA-mediated ceRNA regulatory network.
  • Validated key molecular targets using Polymerase Chain Reaction (PCR) in an animal model.

Main Results:

  • Established the first circRNA-mediated ceRNA regulatory network for myocardial hypertrophy.
  • Identified three key mRNAs (Col12a1, Thbs1, Tgfbr3).
  • Identified four key miRNAs (miR-20a-5p, miR-27b-3p, miR-342-3p, miR-378a-3p).
  • Identified four key circRNAs (circ_0002702, circ_0110609, circ_0013751, circ_0047959) potentially crucial for cardiac hypertrophy.

Conclusions:

  • The study presents a novel circRNA-ceRNA network associated with cardiac hypertrophy.
  • Specific circRNAs, mRNAs, and miRNAs identified may serve as critical regulators or therapeutic targets for cardiac hypertrophy.